Trevena CEO to Present at the 2011 UBS Global Life Sciences Conference
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc., a clinical stage pharmaceutical company focused on discovering and developing the next generation of G-protein coupled receptor (GPCR) targeted medicines, announced today that it will participate in the 2011 UBS Global Life Sciences Conference in New York. Maxine Gowen, Ph.D., president and chief executive officer of Trevena, will make a presentation on Wednesday, September 21, 2011 at 10:00 a.m. EDT. Trevena’s most advanced program, TRV027, is a biased AT1R ligand currently in Phase 2 studies for the treatment of acute heart failure. The company also has discovery-stage and preclinical programs targeting opioid receptors for pain.
About Trevena and Biased Ligands
Trevena, Inc. is the leader in the discovery and development of GPCR “biased ligand” drugs. Trevena combines a powerful and efficient drug discovery platform with extensive development experience to yield a rich linked portfolio of novel medicines. The company's drug discovery technology is based on extensive research from the laboratories of leading scientists in the GPCR field - Robert J. Lefkowitz, M.D. and Howard A. Rockman, M.D. of Duke University Medical Center. Founded in 2008, Trevena is based in King of Prussia, Pennsylvania and is a privately held company backed by leading investors including Alta Partners, Healthcare Ventures, NEA, Polaris and Yasuda Enterprise Development Company. For more information about the company, please visit www.trevenainc.com.
Arthur Fratamico, 610-354-8840
Chief Business Officer
Source: Trevena, Inc.
Released September 15, 2011